Trial site
The Medical Oncology Centre of Rosebank
Johannesburg, Gauteng 2196, South AfricaNot linked to an institution yet
- 12running trials
- 2closed trials
The trials here
What the 14 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 21 trial
- Status
- Active, not recruiting10 trials
- Recruiting2 trials
- Completed1 trial
- Terminated1 trial
- Lead sponsor
- Gilead Sciences3 trials
- Pfizer3 trials
- Amgen2 trials
- Regeneron Pharmaceuticals2 trials
- Eli Lilly and Company1 trial
- and 3 more
Running trials
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555· Phase 3· Amgen· Source
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT05608291· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· Phase 3· Gilead Sciences· Source
Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT05352672· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· Phase 3· HUYABIO International, LLC.· Source
Active, not recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· Phase 3· Pfizer· Source
Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Source
Contact: Jacob Vinson
Active, not recruiting
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error